Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin, Natamycin and Others}, Allylamines {Butenafine, Terbinafine and Naftifine}, and Others], Infection Type [Superficial Antifungal Infection and Systemic Antifungal Infection], Dosage form [Drugs, Ointment, Powder and Others] and Therapeutic Indication [Aspergillosis, Dermatophytosis, Candidiasis, and Others] - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ALL1298423
  • 190 Pages
  • June 2017
  • Pharmaceuticals

Antifungal drugs are used to treat fungal infections, which occur due to unclean, humid, and unhygienic environments. These infections are caused by organisms, which live by feeding on living tissue and are commonly known as dermatophytes that are responsible for the infection of hair, skin and nail as they can utilize keratin. In addition, fungal infections can cause harm to superficial (skin, mouth, and vagina) and systemic parts of the body (lungs, bones, brain, eyes, and others) Some of the common fungal infections such as athlete’s foot, fungal meningitis, ringworm and other infections can be treated by antifungal drugs that work by killing of the fungal cell breaking the contents of the cell. These cells eventually leak out and results in the death of the cell, which also prevents the cell to grow further, thus preventing the infection. The global antifungal drugs market was valued at $13,719 million in 2016, and is expected to reach at $17,718 million by 2023, registering a CAGR of 3.7% from 2017 to 2023.

There are various modes of anti-fungal drug delivery that increases adoption of this products leading to high growth of this market. In addition, absorption of drugs works differently for each individual. Hence, advancement in drug delivery technology is expected to boost the growth of the global antifungal drug market. Further, growing incidence and prevalence rate of infectious diseases and growth in population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period.

The global antifungal drugs market is segmented based on drug type, therapeutic indications, infection type, and geography. Based on drug type, the market is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. Further, based on therapeutic indications, it is classified into aspergillosis, dermatophytosis, candidiasis, others. Based on infection type, the market is bifurcated into superficial and systemic antifungals.

Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals, However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.


  • The study provides an in-depth analysis of the global antifungal drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry, which helps understand the type of products and technologies used globally, is also included.
  • Key market players and their strategies are provided to understand the competitive outlook of the market.


By Drug Type

  • Echinocandins
    • Caspofungin
    • Micafungin
    • Anidulafungin
    • Others
  • Azoles
    • Imidazoles
    • Voriconazole
    • Thiazoles
    • Others
  • Polyenes
    • Amphotericin B
    • Candicidin
    • Hamycin
    • Natamycin
    • Others
  • Allylamines
    • Butenafine
    • Terbinafine
    • Naftifine
    • Others

By Infection Type

  • Superficial Antifungal Infections
  • Systemic Antifungal Infections

 By Therapeutic Indications

  • Aspergillosis
  • Dermatophytosis
  • Candidiasis
  • Others

By Dosage Forms

  • Powders
  • Ointments
  • Drugs
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia-pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
    • Brazil
    • Argentina
    • Egypt
    • Israel
    • South Africa
    • Rest of LAMEA


  • Pfizer Inc.
  • Sanofi S.A.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Scynexis Inc.
  • Novartis International AG
  • Abbott Laboratories
  • Bayer AG
  • Enzon Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc.  

The other players in the value chain include (profiles not included in the report)

  • Sigma-Aldrich Corporation
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc. (a subsidiary of Danaher Corporation)
  • Tecan Group
  • Astellas Pharma, Inc.
  • Basilea Pharmaceutical Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Kramer Laboratories
Please Select Format

Enquiry About Report

Need More Information

Contact us
+ 1-800-910-6452
+91 20 66346066
--- or ---



Global General Medicine Education Publishing Market (Type, Geography) Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Opportunities, Segmentation, Forecast (2013-2020)

General medicine is a branch of medicine that deals with diagnosis and treatment of diseases associated with internal organs. It is also called as Internal Medicine. General medicine education market has shown substantial growth due to the adoption of internal medicine as a career option by medical students.

April 2018| $5370 | Pre Book Price:$4699

Cancer Vaccine Market Global Scenario, Market Size, Outlook, Trend and Forecast, 2015- 2024

Cancer vaccines are biological response modifiers. These vaccines work by stimulating or restoring the immune system�s ability to fight against infections and diseases. It is used either as stand-alone therapies ...

April 2018| $4995 | Pre Book Price:$4371

World Active Pharmaceutical Ingredient (API) Market - Opportunities and Forecasts, 2014 - 2020

Increase in Abbreviated New Drug Applications (ANDA) over the past years has fostered the demand for API market. Furthermore, Indian companies making increased entries related to Drug Master File (DMF) ...

April 2018| $5370 | Pre Book Price:$4699

Anterior Uveitis Asia-Pacific Market Research Report, 2014 - 2020

Anterior uveitis is an eye inflammation that involves middle layer of the eye specifically, iris (colored part of the eye) and ciliary body (adjacent tissue). Untreated anterior uveitis results in ...

April 2018| $2850 | Pre Book Price:$2494

Nanomedicine Asia-Pacific Market Research Report, 2014 - 2020

Nanomedicine is the applied branch of nanotechnology. Application of nanomedicines ranges from nonmaterial to nanoelectronic and in the near future, it could possibly expand to molecular nanotechnology. Biological, pharmaceutical and ...

April 2018| $2850 | Pre Book Price:$2494

Autoimmune Disorders Treatment Asia-Pacific Market Research Report, 2014 - 2020

Graves disease, Multiple sclerosis, Myasthenia gravis, Rheumatoid arthritis, Pernicious anemia and Systemic lupus erythematosus are the most prevalent types of autoimmune disorders. The prevalence of autoimmune diseases is high in ...

April 2018| $2850 | Pre Book Price:$2494

2018 © Copyright Big Market Research

View Pricing >>